Great webinar, just finished.
Yuman is sounding extremely confident about CF33 being a "universal platform" for attacking all cancer types - through the OnCARlytics tech. It can be modified to force cancers to express any required target protein - matching it with any new targeted cancer therapy.
He is also sounding very confident about the Vaxinia trial - confirms again that it is "killing cancer" and changing the tumour micro-environment so that the immune system sees and attacks the cancer as well. Confirms also that the FDA has allowed them to accelerate the original dosage regime for the Check-vacc trial.
In response to a question he confirms that he expects IV administration to be effective. The partnership with RenovoRx is simply to expand options for treatment of "hard to reach" cancer types - and specifically Pancreatic Cancer. He went on to confirm that he believes Intra-peritoneal administration will also be effective, as per the recent pre-clinical studies.
The share price may look discouraging - but the science and the speed at which the science is progressing are all "buy" signals for me.
Cheers
Dave
- Forums
- ASX - By Stock
- IMU
- Ann: Imugene Corporate Presentation
Ann: Imugene Corporate Presentation, page-117
-
- There are more pages in this discussion • 130 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMU (ASX) to my watchlist
|
|||||
Last
5.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $418.9M |
Open | High | Low | Value | Volume |
5.7¢ | 5.7¢ | 5.7¢ | $102.5K | 1.798M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
18 | 1644322 | 5.6¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
5.7¢ | 521325 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 11337 | 0.085 |
1 | 51572 | 0.062 |
1 | 13052 | 0.058 |
11 | 896939 | 0.057 |
15 | 1593428 | 0.056 |
Price($) | Vol. | No. |
---|---|---|
0.055 | 100000 | 1 |
0.056 | 468001 | 4 |
0.057 | 1228070 | 2 |
0.058 | 100863 | 2 |
0.059 | 466527 | 6 |
Last trade - 10.07am 16/07/2024 (20 minute delay) ? |
Featured News
IMU (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online